AVTX — Avalo Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $16.48m
- $9.07m
- $1.92m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 11.2 | 18.9 | 54.6 | 13.2 | 7.42 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5.24 | 4.39 | 4.8 | 1.92 | 0.136 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 17.7 | 26 | 61.8 | 16.4 | 8.39 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.45 | 1.61 | 2.69 | 2.41 | 1.97 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 36.1 | 43.8 | 80.2 | 33.4 | 21 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 12.2 | 15.2 | 19.9 | 22.1 | 4.62 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 15.1 | 19.2 | 57.1 | 44.3 | 13.7 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 21 | 24.6 | 23.1 | -10.9 | 7.3 |
Total Liabilities & Shareholders' Equity | 36.1 | 43.8 | 80.2 | 33.4 | 21 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |